Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — SG&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — sg&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — SG&A?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — SG&A of $41.32M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — SG&A changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — SG&A increased by 22.6% year-over-year, from $33.72M to $41.32M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — SG&A?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — SG&A has grown at a 9.1% compound annual growth rate (CAGR), from $109.78M to $142.38M.
- What does affordable medicines — SG&A mean?
- Encompasses the operating expenses required to support the Affordable Medicines segment, including marketing, sales force compensation, and general corporate overhead. This metric measures the operational efficiency and administrative discipline of the business unit.